Effects of Dapagliflozin on Progression of Alport Syndrome
- Conditions
- Alport Syndrome
- Registration Number
- NCT06226896
- Lead Sponsor
- Nanjing University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 222
Inclusion Criteria:<br><br> - Histologic or genetic confirmation of Alport syndrome;<br><br> - eGFR = 30 ml/min/1.72m2;<br><br> - Proteinuria > 0.5 g/24 h;<br><br> - Use of an ACE inhibitor or ARB, dose stable for more than 4 weeks;<br><br>Exclusion Criteria:<br><br> - Concurrence of other types of kidney disease;<br><br> - type 1 or type 2 diabetes;<br><br> - use of other types of sodium-glucose cotransporter 2 inhibitors within the month<br> prior to enrollment, or prior allergy to such drugs;<br><br> - ACEI combined with ARB, or direct renin inhibitors, aldosterone receptor<br> antagonists;<br><br> - Uncontrolled hypertension (blood pressure greater than 160/90 mmHg during<br> screening);<br><br> - Patients undergoing renal transplantation or maintenance dialysis treatment;<br><br> - Coexist with other serious and/or unstable diseases, such as serious cardiovascular<br> diseases, respiratory diseases, liver diseases or neuropsychiatric diseases;<br><br> - Patients who are participating in clinical trials of other drugs;<br><br> - Pregnant or lactating women, or patients who do not want to receive contraception.
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of eGFR
- Secondary Outcome Measures
Name Time Method Change of proteinuria;Progression of kidney disease